Ingrezza sales and total prescriptions grew 25% and 32% respectively in Q4 from a year ago, the drugmaker said. The drug is indicated to treat adults with tardive dyskinesia, a condition linked to uncontrollable, abnormal, and repetitive movements of the face, torso, and/or other body parts.
Neurocrine plans to provide full-year 2022 Ingrezza sales guidance in its Q4 results on Feb. 11.
Price: 82.5, Change: -0.03, Percent Change: -0.04
|Street Color: Global Calendar For Week Ending May 20|
|Ryder System Receives $4.4 Billion Cash Buyout Propo...|
|Payoneer Shares Rally After Q1 Beats Expectations, 2...|
|Market Chatter: Alibaba Group's Venture in Russia Re...|
|Research Alert: CFRA Raises View On Paycom Software ...|